CN118962125A - A method for processing fluorescent immunochromatography test data - Google Patents
A method for processing fluorescent immunochromatography test data Download PDFInfo
- Publication number
- CN118962125A CN118962125A CN202411436903.4A CN202411436903A CN118962125A CN 118962125 A CN118962125 A CN 118962125A CN 202411436903 A CN202411436903 A CN 202411436903A CN 118962125 A CN118962125 A CN 118962125A
- Authority
- CN
- China
- Prior art keywords
- solution
- abnormal
- specific
- light spot
- fluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明公开了一种荧光免疫层析测试数据的处理方法，涉及层析测试数据处理技术领域，本发明首先进行基础层析测试，进而得到各异常溶液和各异常溶液的各异常体，接着进行特异层析测试，设置初始特异层析测试，根据各异常溶液的标准浓度的各特异测试数据，进而判断是否需要稀释特异层析测试，当需要稀释特异层析测试时，对各异常溶液的各稀释溶液的各特异测试数据进行分析，得到各异常溶液的异常体种类和异常体浓度，最后对各溶液的基础数据和各异常溶液的异常体种类和异常体浓度进行分析，判断是否需要进行预警，本发明可以有效处理荧光免疫层析测试数据，提高测试结果的精确性和可靠性。
The invention discloses a method for processing fluorescent immunochromatography test data, and relates to the technical field of chromatography test data processing. The invention first performs a basic chromatography test to obtain various abnormal solutions and various abnormal bodies of various abnormal solutions, then performs a specific chromatography test, sets an initial specific chromatography test, and judges whether it is necessary to dilute the specific chromatography test according to various specific test data of the standard concentration of each abnormal solution. When it is necessary to dilute the specific chromatography test, the various specific test data of each diluted solution of each abnormal solution are analyzed to obtain the abnormal body type and abnormal body concentration of each abnormal solution. Finally, the basic data of each solution and the abnormal body type and abnormal body concentration of each abnormal solution are analyzed to judge whether it is necessary to issue an early warning. The invention can effectively process fluorescent immunochromatography test data and improve the accuracy and reliability of the test results.
Description
Technical Field
The invention relates to the technical field of chromatographic test data processing, in particular to a method for processing fluorescent immunochromatographic test data.
Background
The fluorescent immunochromatography technology is a method for efficiently and rapidly detecting specific pathogens in biological samples, and has been widely applied in the fields of medicine, agriculture and the like. With the continued development of fluorescent immunochromatography, the amount of data generated by the test is becoming larger and larger, and how to efficiently process and analyze such data becomes more and more important.
The prior art, for example, the patent application of the invention with the publication number of CN107389625B discloses a method for processing fluorescence immunochromatography test data, which comprises the steps of providing an immunochromatography test strip, an excitation light source and a laser reading device, controlling light spots through the control device so that the light spots move along the length direction of the chromatography test strip, and processing data corresponding to the signal intensities of the effective light spots, thereby obtaining the detection result of the immunochromatography test strip. The method of the invention eliminates the sample loss quantity between batches, the sample addition quantity difference between batches, partial interference factors in the antibody marking process and the like introduced on the quality control line, so that the final data result has reasonable physical significance and higher sensitivity.
Aiming at the scheme, the invention discovers that the technology at least has the following technical problems: on the one hand, the scheme is a method for detecting an abnormal body by using immunochromatographic test paper, the solution to be detected is not pre-detected, if a certain solution to be detected has a plurality of abnormal bodies to be detected, the method needs to perform one-to-one experiment on the solution to be detected, so that the detection and analysis cost is increased, on the other hand, the scheme is used for detecting a single solution, the influence of the plurality of abnormal bodies on the chromatographic test paper is not considered, the false positive is easily caused, the detection precision is influenced, the error data is easily acquired, and the sensitivity is reduced.
Disclosure of Invention
In view of the above-mentioned technical shortcomings, the present invention aims to provide a method for processing fluorescence immunochromatography test data.
In order to solve the technical problems, the invention adopts the following technical scheme: the invention provides a method for processing fluorescence immunochromatography test data, which comprises the following steps: step one, basic chromatography test: and (3) performing basic chromatography test on each object to be tested to obtain a fluorescence diagram of each solution, further collecting basic chromatography information of each solution from the fluorescence diagram of each solution, analyzing the basic chromatography information of each solution to obtain each abnormal solution, and identifying each abnormal body of each abnormal solution from each abnormal solution.
Step two, specific chromatography test: according to the different body of the different solution, setting an initial specific chromatography test, collecting the specific test data of the standard concentration of the different solution, further judging whether the specific chromatography test needs to be diluted, when the specific chromatography test is performed, collecting the specific test data of the diluted solution of the different solution, and according to a solution specific model, analyzing the specific test data of the diluted solution of the different solution to obtain the abnormal body type and the abnormal body concentration of the different solution.
Step three, chromatographic data analysis: and acquiring solution basic data from the database, analyzing the solution basic data, the abnormal body types and the abnormal body concentrations of the abnormal solutions according to the solution abnormal model, and judging whether early warning is needed or not.
Preferably, the analysis is performed on each specific test data of each diluted solution of each abnormal solution, and the specific analysis results are as follows: the specific test data of each diluted solution of each abnormal solution comprises each abnormal body of each diluted solution of each abnormal solution and the corresponding spot size of each abnormal body, the abnormal bodies of each diluted solution of each abnormal solution are counted to obtain the occurrence times of each abnormal body of each abnormal solution, the specific spot size of each diluted solution of each abnormal solution is substituted into a calculation formula to obtain the concentration of each abnormal body of each diluted solution of each abnormal solution, the standard concentration corresponding to each abnormal body is obtained from a database, and if the concentration of each abnormal body of a certain diluted solution of a certain solution is larger than the standard concentration, the concentration of each abnormal body of the diluted solution of the certain solution is indicated to be high, and the occurrence times of each abnormal body of each abnormal solution are counted to obtain the occurrence times of each abnormal body of the certain abnormal solution.
Inputting the occurrence times and the high concentration occurrence times of the abnormal bodies of the abnormal solutions into a solution specific model to obtain output results of the abnormal solutions, if the output results of the abnormal solutions are 1, the dilution specific test of the abnormal bodies of the abnormal solutions is accurate, and if the output results of the abnormal solutions are 0, the dilution specific test of the abnormal bodies of the abnormal solutions is inaccurate, and the dilution solution is replaced to continue the dilution specific chromatography test.
Preferably, the analysis is performed on the solution basic data, the abnormal species and the abnormal concentration of each abnormal solution, and the specific analysis process is as follows: the basic solution data comprise standard concentrations and maximum concentrations corresponding to abnormal bodies, the standard concentrations corresponding to the abnormal bodies are input into a solution abnormal model to obtain output results of the solutions, if the output result of a certain solution is 1 and the concentration of each abnormal body of the solution is smaller than the maximum concentration of the corresponding abnormal body, the solution is indicated to be in accordance with the rule, if the output result of the certain solution is 0 or the concentration of the abnormal body of the solution is greater than or equal to the maximum concentration of the corresponding abnormal body, the solution is indicated to be abnormal, and warning is carried out.
The invention has the beneficial effects that: 1. according to the invention, the basic chromatography test is firstly carried out, each object to be tested is subjected to the basic chromatography test to obtain a fluorescence image of each solution, then the basic chromatography information of each solution is collected from the fluorescence image of each solution, then the specific chromatography test is carried out, according to each abnormal body of each abnormal solution, the initial specific chromatography test is set, each specific test data of standard concentration of each abnormal solution is collected, and then whether the specific chromatography test needs to be diluted or not is judged, when the specific chromatography test needs to be diluted, each specific test version data of each diluted solution of each abnormal solution is collected, according to a solution specific model, each specific test version data of each diluted solution of each abnormal solution is analyzed to obtain abnormal body type and abnormal body concentration of each abnormal solution, then the basic data of each solution and the abnormal body type and abnormal body concentration of each abnormal solution are analyzed, and whether pre-warning is needed or not is judged.
2. According to the invention, whether the initial specific chromatography test data are accurate or not is judged by comparing the analysis result of the initial specific chromatography test data with the analysis result of the basic chromatography test data, if so, the initial specific chromatography test data are recorded as the specific chromatography test data, and if not, the analysis result of the diluted specific chromatography test is recorded as the specific chromatography test data by diluting the specific chromatography test.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a flow chart of the steps of the method of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
According to FIG. 1, the invention provides a method for processing fluorescence immunochromatography test data, which comprises the following steps: step one, basic chromatography test: and (3) performing basic chromatography test on each object to be tested to obtain a fluorescence diagram of each solution, further collecting basic chromatography information of each solution from the fluorescence diagram of each solution, analyzing the basic chromatography information of each solution to obtain each abnormal solution, and identifying each abnormal body of each abnormal solution from each abnormal solution.
In a specific embodiment, the collecting basic chromatographic information of each solution is as follows: the basic chromatographic information of each solution includes the distance and fluorescence intensity of each spot within each solution.
And obtaining the types of the objects to be detected from the database, selecting a fixed plate for detecting antigens according to the types of the objects to be detected, preparing the objects to be detected into solutions, washing part of the solutions to be detected into the fixed plate, obtaining a fluorescence diagram of each basic chromatographic solution through a fluorescence observation device after chromatography, and obtaining basic chromatographic information of each solution from the fluorescence diagram of each basic chromatographic solution.
It should be noted that, the analyte refers to an article to be detected, such as blood, food or medicine, and different antigens to be detected by different analytes, and meanwhile, if the antigen to be detected is obtained, the specific chromatographic detection is directly performed without performing the basic chromatographic test.
The fluorescence graph of each basic chromatographic solution obtains each distance and fluorescence brightness from each light spot to a test line through a fluorescence identification technology, and the shortest distance from each light spot to the test line is selected and recorded as the distance from each light spot, so that the distance and fluorescence brightness of each light spot in each solution are obtained.
The fluorescence recognition technology recognizes each fluorescence spot by the brightness of each pixel on the fluorescence image, the shortest distance is the antigen moving distance, and the diffusion distances of different antigens on the fixative are different.
In one embodiment, the analysis of the basic chromatographic information of each solution is performed as follows: obtaining the fluorescence brightness and the distance of each light spot of the standard solution from the database, and substituting the fluorescence brightness and the distance of each light spot of the standard solution into a calculation formulaAndObtaining brightness deviation value between x light spots of standard solutionAndThe distance deviation value, x is the light spot number,，，AndRespectively the fluorescence brightness and the distance of the light spot x,AndAnd respectively obtaining the fluorescence brightness and the distance of each light spot of the standard solution, if the brightness deviation value of a certain pair of light spots of the standard solution is smaller than the preset light spot deviation value and the distance deviation value is smaller than the preset distance deviation value, indicating that the pair of light spots of the standard solution are the same type of normal light spots, obtaining various normal light spots, and counting the fluorescence brightness and the distance of each light spot of the standard solution to obtain the fluorescence brightness and the distance of each normal light spot.
It should be noted that, the preset light spot deviation value and the preset distance deviation value are set for the staff, for example, the preset light spot deviation value is 0.13 and the preset distance deviation value is 0.11.
The maximum fluorescence brightness and the minimum fluorescence brightness of each normal light spot are respectively marked as the upper limit and the lower limit of a fluorescence brightness interval, so as to obtain each normal light spot fluorescence brightness interval, the shortest distance and the minimum distance of each normal light spot are respectively marked as the upper limit and the lower limit of a distance interval, so as to obtain each normal light spot distance interval, if the fluorescence brightness of a certain light spot does not belong to the fluorescence brightness interval of each normal light spot, or the fluorescence brightness of the light spot does not belong to the distance interval of each normal light spot, the light spot is indicated to be a specific light spot, if the light spot of a certain solution is a specific light spot, the solution is marked as an abnormal solution, the fluorescence brightness interval of each specific light spot is obtained from a database, and if the fluorescence brightness of the certain light spot of a certain abnormal solution belongs to the fluorescence brightness interval of a certain specific light spot, the abnormal solution is indicated to have an abnormal body corresponding to the specific light spot, so as to obtain each abnormal body of each abnormal solution.
The abnormal body is the object of the fluorescent immunochromatography test, such as virus or bacteria, the number of the abnormal body is g, the abnormal body can be combined with the corresponding antibody on the fixed plate, the combined body can react with the fluorescent reagent to generate fluorescence, the light spot is the combined body of the fluorescent marked abnormal body and the corresponding antibody, when the solution to be tested contains any abnormal body, the solution to be tested is the abnormal solution, for example, the g antibody has a fluorescence brightness interval of 6-8 corresponding to a specific light spot, and when the brightness interval of a light spot c of the solution a is 7, the solution a containsThe antibody corresponds to the abnormal body g, and further indicates that the solution a is an abnormal solution.
Step two, specific chromatography test: according to the different body of the different solution, setting an initial specific chromatography test, collecting the specific test data of the standard concentration of the different solution, further judging whether the specific chromatography test needs to be diluted, when the specific chromatography test is performed, collecting the specific test data of the diluted solution of the different solution, and according to a solution specific model, analyzing the specific test data of the diluted solution of the different solution to obtain the abnormal body type and the abnormal body concentration of the different solution.
In a specific embodiment, the initial specific chromatography test is set up as follows: and diluting the various abnormal solutions with preset dilution ratio to obtain standard concentration diluted solutions of the various abnormal solutions, selecting corresponding antigen fixing plates according to the abnormal bodies of the various abnormal solutions to obtain various antigen fixing plates of the various abnormal solutions, and flowing the standard concentration diluted solutions of the various abnormal solutions into the corresponding various antigen fixing plates to obtain various antigen fluorescent maps of the various abnormal solutions.
In one embodiment, the determination of whether a dilution-specific chromatography test is required is performed as follows: the specific test data of the standard concentration of each abnormal solution comprises the fluorescence brightness and the distance of each light spot in each antigen fluorescence graph of each abnormal solution of the standard concentration, if the fluorescence brightness of any light spot in a certain antigen fluorescence graph belongs to the fluorescence brightness interval corresponding to the antigen, and the distance of the light spot belongs to the distance interval corresponding to the antigen, the antigen fluorescence graph has specific light spots, if a certain antigen fluorescence graph of a certain abnormal solution has specific light spots, the standard concentration abnormal solution has the abnormal body, if the abnormal body of the standard concentration diluted solution of a certain abnormal solution is identical with the abnormal body of the abnormal solution, the abnormal solution initial specific chromatography test is accurate, the specific chromatography test is not required to be diluted, the size of each specific light spot of each solution with accurate initial specific chromatography test is acquired, and the size of each specific light spot of each solution with accurate initial specific chromatography test is substituted into the concentration calculation formulaObtaining the concentration of the abnormal body b of the abnormal solution aA is the number of the abnormal solution,，B is an abnormal body,，，AndSpot size and mobile phase wetting test paper size of the initial specific chromatography test of the abnormal body b of the abnormal solution a respectively,For the preset concentration correction factor,AndFor the initial specific chromatography test of the abnormal body b of the abnormal solution a,AndThe volume of the diluted solution and the volume of the solution before dilution are respectively preset for the abnormal solution a.
The concentration correction factor is set by a worker, for example, 1.5.
In one embodiment, the dilution-specific chromatography test is performed as follows: diluting each abnormal solution with each dilution ratio to obtain each diluted solution of each abnormal solution, performing a specific chromatography test to obtain each antigen fluorescent image of each diluted solution of each abnormal solution, obtaining the fluorescent brightness and the distance of each light spot from each antigen fluorescent image, and judging according to the fluorescent brightness and the distance of each light spot on each antigen fluorescent image of each diluted solution of each abnormal solution to obtain each abnormal body of each diluted solution of each abnormal solution and the light spot size corresponding to each abnormal body.
In one embodiment, the specific test data for each diluted solution of each abnormal solution is analyzed as follows: the specific test data of each diluted solution of each abnormal solution comprises each abnormal body of each diluted solution of each abnormal solution and the corresponding spot size of each abnormal body, the abnormal bodies of each diluted solution of each abnormal solution are counted to obtain the occurrence times of each abnormal body of each abnormal solution, and the specific spot size of each diluted solution of each solution is substituted into a calculation formulaIn the above, the concentration of the abnormal body b of the diluted solution c of the abnormal solution a is obtained, c is the number of the diluted solution,，，AndSpot size and mobile phase wetting test paper size of the specific chromatographic test are respectively diluted by an abnormal body b of a c diluted solution of the abnormal solution a,AndFor diluting the solution use volume and the solution use mass of the specific chromatography test for the abnormal body b of the c diluted solution of the abnormal solution a,AndThe diluted solution volume and the solution volume before dilution corresponding to the diluted solution c of the abnormal solution a respectively,Spot size for outlier b test of c dilution solution for outlier a,The volume of solution used for the abnormal body b test of the c-diluted solution of abnormal solution a,AndAnd c, respectively obtaining the standard concentration corresponding to each abnormal body from a database, wherein the diluted solution volume and the pre-diluted solution volume of the diluted solution of the abnormal solution a are respectively the diluted solution volume and the pre-diluted solution volume of the diluted solution, if the concentration of a certain abnormal body of a certain diluted solution of a certain solution is larger than the standard concentration, the concentration of the abnormal body of the diluted solution of the solution is high, and counting to obtain the occurrence times of each abnormal high concentration of each abnormal solution.
Inputting the occurrence times and the high concentration occurrence times of the abnormal bodies of the abnormal solutions into a solution specific model to obtain output results of the abnormal solutions, if the output results of the abnormal solutions are 1, the dilution specific test of the abnormal bodies of the abnormal solutions is accurate, and if the output results of the abnormal solutions are 0, the dilution specific test of the abnormal bodies of the abnormal solutions is inaccurate, and the dilution solution is replaced to continue the dilution specific chromatography test.
In a specific embodiment, the solution specific model is specifically set up as follows: inputting the occurrence times and the high concentration occurrence times of the different abnormal solutions into a solution specific model: Obtaining the output result of various abnormal solutions A is the number of the abnormal solution,，B is an abnormal body,，，AndThe occurrence times of abnormal bodies and the occurrence times of high concentration of the abnormal solution a are respectively shown in the specification, A and B are respectively shown in the specification,AndRespectively a weight factor of the occurrence number of the preset standard abnormal body and a weight factor of the occurrence number of the high concentration,，，C is the standard test precision index.
The preset number of occurrences of the standard abnormal body and the number of occurrences of the high concentration are set by the worker, for example, the number of occurrences of the standard abnormal body is 8 times and the number of occurrences of the high concentration is 1 time, and the weight factor of the number of occurrences of the standard abnormal body and the weight factor of the number of occurrences of the high concentration are set by the worker, for example, the weight factor of the number of occurrences of the standard abnormal body is 0.3 and the weight factor of the number of occurrences of the high concentration is 0.7.
In one embodiment, the analysis is performed on the solution base data, the abnormal species and the abnormal concentration of each abnormal solution, and the specific analysis process is as follows: the basic solution data comprise standard concentrations and maximum concentrations corresponding to abnormal bodies, the standard concentrations corresponding to the abnormal bodies are input into a solution abnormal model to obtain output results of the solutions, if the output result of a certain solution is 1 and the concentration of each abnormal body of the solution is smaller than the maximum concentration of the corresponding abnormal body, the solution is indicated to be in accordance with the rule, if the output result of the certain solution is 0 or the concentration of the abnormal body of the solution is greater than or equal to the maximum concentration of the corresponding abnormal body, the solution is indicated to be abnormal, and warning is carried out.
In a specific embodiment, the solution abnormality model is specifically set as follows: inputting the standard concentration corresponding to each abnormal body into a solution abnormal model: obtaining the output result of the abnormal solution a ，AndThe concentration of an abnormal body b of the abnormal solution a and the standard concentration corresponding to the preset abnormal body b are respectively, a is the number of the abnormal solution,，B is an abnormal body,，，Is a weight factor of the preset abnormal body b concentration,，N is the abnormality index of the standard solution.
It should be noted that, the preset standard concentration corresponding to each abnormal body is set by a worker, for example, the standard concentration corresponding to a certain abnormal body is 10000cfu/g, and the preset weight factor of each abnormal body concentration is set by the worker, for example, the weight factor of a certain abnormal body concentration is 0.08.
The foregoing is merely illustrative and explanatory of the principles of the invention, as various modifications and additions may be made to the specific embodiments described, or similar arrangements may be substituted by those skilled in the art, without departing from the principles of the invention or beyond the scope of the invention as defined in the description.
Claims (10)
1. The method for processing the fluorescence immunochromatography test data is characterized by comprising the following steps of:
step one, basic chromatography test: performing basic chromatography test on each object to be tested to obtain a fluorescence graph of each solution, further collecting basic chromatography information of each solution from the fluorescence graph of each solution, analyzing the basic chromatography information of each solution to obtain each abnormal solution, and identifying each abnormal body of each abnormal solution from each abnormal solution;
Step two, specific chromatography test: setting an initial specific chromatography test according to each abnormal body of each abnormal solution, collecting each specific test data of the standard concentration of each abnormal solution, further judging whether the specific chromatography test needs to be diluted, collecting each specific test data of each diluted solution of each abnormal solution when the specific chromatography test is carried out, and analyzing each specific test data of each diluted solution of each abnormal solution according to a solution specific model to obtain the abnormal body type and the abnormal body concentration of each abnormal solution;
Step three, chromatographic data analysis: and acquiring solution basic data from the database, analyzing the solution basic data, the abnormal body types and the abnormal body concentrations of the abnormal solutions according to the solution abnormal model, and judging whether early warning is needed or not.
2. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein the basic chromatographic information of each solution is collected, and the specific collection process is as follows:
The basic chromatographic information of each solution comprises the distance and fluorescence brightness of each light spot in each solution;
Obtaining the types of all the objects to be detected from a database, selecting a fixed plate for detecting antigens according to the types of all the objects to be detected, preparing all the objects to be detected into solutions, washing part of the solutions of all the solutions to be detected into the fixed plate, obtaining a fluorescence diagram of each basic chromatographic solution through a fluorescence observation device after chromatography, and obtaining basic chromatographic information of each solution from the fluorescence diagram of each basic chromatographic solution;
The fluorescence graph of each basic chromatographic solution obtains each distance and fluorescence brightness from each light spot to a test line through a fluorescence identification technology, and the shortest distance from each light spot to the test line is selected and recorded as the distance from each light spot, so that the distance and fluorescence brightness of each light spot in each solution are obtained.
3. The method for processing fluorescence immunochromatographic test data according to claim 2, wherein the basic chromatographic information of each solution is analyzed by the following specific analysis process:
Obtaining the fluorescence brightness and the distance of each light spot of the standard solution from a database, substituting the fluorescence brightness and the distance of each light spot of the standard solution into a calculation formula to obtain brightness deviation values and distance deviation values between each light spot of the standard solution, if the brightness deviation values of a certain pair of light spots of the standard solution are smaller than preset light spot deviation values and the distance deviation values are smaller than preset distance deviation values, indicating that the pair of light spots of the standard solution are the same type of normal light spots, so as to obtain various normal light spots, and counting the fluorescence brightness and the distance of each light spot of the standard solution to obtain the fluorescence brightness and the distance of each normal light spot;
The maximum fluorescence brightness and the minimum fluorescence brightness of each normal light spot are respectively marked as the upper limit and the lower limit of a fluorescence brightness interval, so as to obtain each normal light spot fluorescence brightness interval, the shortest distance and the minimum distance of each normal light spot are respectively marked as the upper limit and the lower limit of a distance interval, so as to obtain each normal light spot distance interval, if the fluorescence brightness of a certain light spot does not belong to the fluorescence brightness interval of each normal light spot, or the fluorescence brightness of the light spot does not belong to the distance interval of each normal light spot, the light spot is indicated to be a specific light spot, if the light spot of a certain solution is a specific light spot, the solution is marked as an abnormal solution, the fluorescence brightness interval of each specific light spot is obtained from a database, and if the fluorescence brightness of the certain light spot of a certain abnormal solution belongs to the fluorescence brightness interval of a certain specific light spot, the abnormal solution is indicated to have an abnormal body corresponding to the specific light spot, so as to obtain each abnormal body of each abnormal solution.
4. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein the initial specific chromatographic test is set up by the following specific setting up procedure:
And diluting the various abnormal solutions with preset dilution ratio to obtain standard concentration diluted solutions of the various abnormal solutions, selecting corresponding antigen fixing plates according to the abnormal bodies of the various abnormal solutions to obtain various antigen fixing plates of the various abnormal solutions, and flowing the standard concentration diluted solutions of the various abnormal solutions into the corresponding various antigen fixing plates to obtain various antigen fluorescent maps of the various abnormal solutions.
5. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein the judging whether the dilution of the specific chromatographic test is required or not is performed comprises the following specific judging steps:
The standard concentration of each abnormal solution comprises the fluorescence brightness and the distance of each light spot in each antigen fluorescence image of each abnormal solution with standard concentration, if the fluorescence brightness of any light spot in a certain antigen fluorescence image belongs to the fluorescence brightness interval corresponding to the antigen, and the distance of the light spot belongs to the distance interval corresponding to the antigen, the antigen fluorescence image is provided with a specific light spot, if a certain antigen fluorescence image of a certain abnormal solution is provided with a specific light spot, the standard concentration abnormal solution is provided with the abnormal body, if the standard concentration diluted solution of a certain abnormal solution is identical to the abnormal body of the abnormal solution, the abnormal solution is accurate in initial specific chromatography test, the specific chromatography test is not required to be diluted, the size of each specific light spot of each solution accurate in initial specific chromatography test is collected, and the size of each specific light spot of each solution accurate in initial specific chromatography test is substituted into a concentration calculation formula to obtain the concentration of each abnormal body of each solution.
6. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein the dilution-specific chromatography test is performed by the following specific test procedures:
diluting each abnormal solution with each dilution ratio to obtain each diluted solution of each abnormal solution, performing a specific chromatography test to obtain each antigen fluorescent image of each diluted solution of each abnormal solution, obtaining the fluorescent brightness and the distance of each light spot from each antigen fluorescent image, and judging according to the fluorescent brightness and the distance of each light spot on each antigen fluorescent image of each diluted solution of each abnormal solution to obtain each abnormal body of each diluted solution of each abnormal solution and the light spot size corresponding to each abnormal body.
7. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein each specific test data of each diluted solution of each abnormal solution is analyzed, and the specific analysis results are as follows:
The specific test data of each diluted solution of each abnormal solution comprises each abnormal body of each diluted solution of each abnormal solution and the corresponding spot size of each abnormal body, the abnormal bodies of each diluted solution of each abnormal solution are counted to obtain the occurrence times of each abnormal body of each abnormal solution, the size of each specific spot of each diluted solution of each abnormal solution is substituted into a calculation formula to obtain the concentration of each abnormal body of each diluted solution of each abnormal solution, the standard concentration corresponding to each abnormal body is obtained from a database, and if the concentration of each abnormal body of a certain diluted solution of a certain solution is higher than the standard concentration, the concentration of each abnormal body of the diluted solution of the certain solution is indicated to be high, and the occurrence times of each abnormal body of each abnormal solution are counted to obtain the occurrence times of each abnormal body of the certain abnormal solution;
inputting the occurrence times and the high concentration occurrence times of the abnormal bodies of the abnormal solutions into a solution specific model to obtain output results of the abnormal solutions, if the output results of the abnormal solutions are 1, the dilution specific test of the abnormal bodies of the abnormal solutions is accurate, and if the output results of the abnormal solutions are 0, the dilution specific test of the abnormal bodies of the abnormal solutions is inaccurate, and the dilution solution is replaced to continue the dilution specific chromatography test.
8. The method for processing fluorescence immunochromatographic test data according to claim 7, wherein the specific solution model is specifically set as follows:
inputting the occurrence times and the high concentration occurrence times of the different abnormal solutions into a solution specific model: Obtaining the output result of various abnormal solutions A is the number of the abnormal solution,，B is an abnormal body,，，AndThe occurrence times of abnormal bodies and the occurrence times of high concentration of the abnormal solution a are respectively shown in the specification, A and B are respectively shown in the specification,AndRespectively a weight factor of the occurrence number of the preset standard abnormal body and a weight factor of the occurrence number of the high concentration,，，C is the standard test precision index.
9. The method for processing fluorescence immunochromatographic test data according to claim 1, wherein the analysis of the solution base data, the abnormal species and the abnormal concentration of each abnormal solution is performed by the following steps:
The basic solution data comprise standard concentrations and maximum concentrations corresponding to abnormal bodies, the standard concentrations corresponding to the abnormal bodies are input into a solution abnormal model to obtain output results of the solutions, if the output result of a certain solution is 1 and the concentration of each abnormal body of the solution is smaller than the maximum concentration of the corresponding abnormal body, the solution is indicated to be in accordance with the rule, if the output result of the certain solution is 0 or the concentration of the abnormal body of the solution is greater than or equal to the maximum concentration of the corresponding abnormal body, the solution is indicated to be abnormal, and warning is carried out.
10. The method for processing fluorescence immunochromatographic test data according to claim 9, wherein the solution abnormality model is specifically set as follows:
Inputting the standard concentration corresponding to each abnormal body into a solution abnormal model: obtaining the output result of the abnormal solution a ，AndThe concentration of an abnormal body b of the abnormal solution a and the standard concentration corresponding to the preset abnormal body b are respectively, a is the number of the abnormal solution,，B is an abnormal body,，，Is a weight factor of the preset abnormal body b concentration,，N is the abnormality index of the standard solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411436903.4A CN118962125A (en) | 2024-10-15 | 2024-10-15 | A method for processing fluorescent immunochromatography test data |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411436903.4A CN118962125A (en) | 2024-10-15 | 2024-10-15 | A method for processing fluorescent immunochromatography test data |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118962125A true CN118962125A (en) | 2024-11-15 |
Family
ID=93399499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411436903.4A Pending CN118962125A (en) | 2024-10-15 | 2024-10-15 | A method for processing fluorescent immunochromatography test data |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118962125A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1148177A (en) * | 1995-03-17 | 1997-04-23 | 株式会社日立制作所 | Automatic analysis device |
| CN1460858A (en) * | 2003-06-27 | 2003-12-10 | 江西中德生物工程有限公司 | Reference immunochromatorgrphic analysis for detecting antigen concentration |
| WO2012050844A1 (en) * | 2010-09-28 | 2012-04-19 | Authentix, Inc. | Determining the quantity of a taggant in a liquid sample |
| WO2015027816A1 (en) * | 2013-08-26 | 2015-03-05 | Tencent Technology (Shenzhen) Company Limited | Devices and methods for acquiring abnormal information |
| CN107389625A (en) * | 2016-09-27 | 2017-11-24 | 上海艾瑞德生物科技有限公司 | Fluorescence immune chromatography test data processing method |
| CN113761456A (en) * | 2021-09-07 | 2021-12-07 | 杭州凯曼健康科技有限公司 | Analysis method, device and electronic device for immunofluorescence chromatography curve |
| CN118757482A (en) * | 2024-09-05 | 2024-10-11 | 江苏南方润滑股份有限公司 | A hydraulic lubrication system abnormality warning method and system for leak detection |
-
2024
- 2024-10-15 CN CN202411436903.4A patent/CN118962125A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1148177A (en) * | 1995-03-17 | 1997-04-23 | 株式会社日立制作所 | Automatic analysis device |
| CN1460858A (en) * | 2003-06-27 | 2003-12-10 | 江西中德生物工程有限公司 | Reference immunochromatorgrphic analysis for detecting antigen concentration |
| WO2012050844A1 (en) * | 2010-09-28 | 2012-04-19 | Authentix, Inc. | Determining the quantity of a taggant in a liquid sample |
| WO2015027816A1 (en) * | 2013-08-26 | 2015-03-05 | Tencent Technology (Shenzhen) Company Limited | Devices and methods for acquiring abnormal information |
| CN107389625A (en) * | 2016-09-27 | 2017-11-24 | 上海艾瑞德生物科技有限公司 | Fluorescence immune chromatography test data processing method |
| CN113761456A (en) * | 2021-09-07 | 2021-12-07 | 杭州凯曼健康科技有限公司 | Analysis method, device and electronic device for immunofluorescence chromatography curve |
| CN118757482A (en) * | 2024-09-05 | 2024-10-11 | 江苏南方润滑股份有限公司 | A hydraulic lubrication system abnormality warning method and system for leak detection |
Non-Patent Citations (2)
| Title |
|---|
| NIANYIN ZENG ET AL.: "Quantitative Analysis of Immunochromatographic Strip Based on Convolutional Neural Network", IEEE ACCESS, vol. 7, 21 January 2019 (2019-01-21), pages 16257 - 16263, XP011709214, DOI: 10.1109/ACCESS.2019.2893927 * |
| 刘畅等: "免疫层析技术研究及应用", 动物医学进展, vol. 42, no. 2, 31 December 2021 (2021-12-31), pages 117 - 121 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10067125B2 (en) | System and method for spatiotemporally analyzed rapid assays | |
| US20230366881A1 (en) | Image quantification system for estimation of viral load based on detection by rapid antigen test | |
| BRPI0622185A2 (en) | Method for the acquisition of a digital image of an agglutination result, Method for the analysis of an agglutination assay, Method for extracting a set of characteristics, Method for obtaining a quantification function f for dilution, Method for the extraction of a quantitative result for each dilution of a sample, method for evaluating an agglutination test and obtaining a semi-quantitative result | |
| CN106645706A (en) | Method for quantitatively analyzing colloidal gold detection reagent by mobile terminal | |
| JP2007033132A (en) | Analyzing system, inspection data processor, computer program and analyzer | |
| CN112161913A (en) | Analysis method and equipment for flow type fluorescence analysis system | |
| CN111323608A (en) | POCT detection equipment with temperature and humidity correction function and detection method | |
| JP6791170B2 (en) | Analytical instruments, analytical methods, and analytical systems | |
| EP3978902B1 (en) | Maturity classification of stained reticulocytes using optical microscopy | |
| Cunliffe et al. | An approach to the validation of flow cytometry methods | |
| JP5543310B2 (en) | Immunochromatographic inspection method and apparatus | |
| WO2020124735A1 (en) | Method for detecting functions of fluorescence immunity analyzer | |
| Čičak et al. | Verification of automatic analysers Roller 20PN and iSED for measuring erythrocyte sedimentation rate | |
| CN118962125A (en) | A method for processing fluorescent immunochromatography test data | |
| EP2623979A1 (en) | Immunochromatographic inspection method and device | |
| CN115356479B (en) | Gold immunochromatography detection method and system | |
| CN103616522A (en) | Immune chromatography result identification method based on envelope area and twice compensation | |
| JP2010117290A (en) | Apparatus and method for analyzing liquid sample constituent | |
| JPS6298262A (en) | Retest processing method in clinical testing system | |
| JP2595267B2 (en) | Methods for measuring substances using photometric evaluation | |
| CN118425118B (en) | Dry-type rapid diagnosis and data integration system | |
| Tumrani et al. | Comparison of In-house Microalbumin Assay with Cobas C311-Methodological Insights and Clinical Implications | |
| Wang et al. | Assay Performance Evaluation | |
| CN118111980A (en) | Rapid quantitative detection method based on smart phone and machine learning | |
| JP2025503838A (en) | Method and apparatus for detecting prozone phenomena in a sample to be detected based on the curvature of the response curve - Patents.com |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |